A carregar...
Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer
BACKGROUND: Gemcitabine (GEM) is the standard of care for pancreatic cancer. Unfortunately, median progression-free survival (PFS) is 2.2 months and overall survival (OS) is 5.65 months. Imatinib mesylate (IM) inhibits the Bcr-Abl tyrosine kinase and receptors for platelet-derived growth factor (PDG...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Society of Gastrointestinal Oncology
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3047035/ |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|